Activity-dependent neuroprotective protein (adnp) and davunetide (nap)

Handbook of Biologically Active Peptides

Volumn , Issue , 2013, Pages 1611-1618

  Gozes, I ^a   Baas, P W ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884959506     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-385095-9.00220-7     Document Type: Chapter

References (35)

1. Bassan M., Zamostiano R., Davidson A., Pinhasov A., Giladi E., Perl O., et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 1999, 72:1283-1293.
2. Belokopytov M., Shulman S., Dubinsky G., Gozes I., Belkin M., Rosner M. Ameliorative effect of NAP on laser-induced retinal damage. Acta Ophthalmol 2011, 89:e126-e131.
3. Brenneman D.E., Gozes I. A femtomolar-acting neuroprotective peptide. J Clin Invest 1996, 97:2299-2307.
4. Chen S., Charness M.E. Ethanol inhibits neuronal differentiation by disrupting activity-dependent neuroprotective protein signaling. Proc Natl Acad Sci U S A 2008, 105:19962-19967.
5. Cosgrave A.S., McKay J.S., Morris R., Quinn J.P., Thippeswamy T. Nitric oxide regulates activity-dependent neuroprotective protein (ADNP) in the dentate gyrus of the rodent model of kainic acid-induced seizure. J Mol Neurosci 2009, 39:9-21.
6. Divinski I., Holtser-Cochav M., Vulih-Schultzman I., Steingart R.A., Gozes I. Peptide neuroprotection through specific interaction with brain tubulin. J Neurochem 2006, 98:973-984.
7. Divinski I., Mittelman L., Gozes I. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem 2004, 279:28531-28538.
8. Dresner E., Agam G., Gozes I. Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia. Eur Neuropsychopharmacol 2011, 21:355-361.
9. Fleming S.M., Mulligan C.K., Richter F., Mortazavi F., Lemesre V., Frias C., et al. A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Mol Cell Neurosci 2011, 46:597-606.
10. Furman S., Steingart R.A., Mandel S., Hauser J.M., Brenneman D.E., Gozes I. Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biol 2004, 1:193-199.
11. Gozes I., Divinski I. NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Curr Alzheimer Res 2007, 4:507-509.
12. Gozes I., Spivak-Pohis I. Neurotrophic effects of the peptide NAP: a novel neuroprotective drug candidate. Curr Alzheimer Res 2006, 3:197-199.
13. Gozes I., Stewart A., Morimoto B., Fox A., Sutherland K., Schmechel D. Addressing Alzheimer's disease tangles: from NAP to AL-108. Curr Alzheimer Res 2009, 6:455-460.
14. Gozes I., Zaltzman R., Hauser J., Brenneman D.E., Shohami E., Hill J.M. The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury. Curr Alzheimer Res 2005, 2:149-153.
15. Idan-Feldman A., Schirer Y., Polyzoidou E., Touloumi O., Lagoudaki R., Grigoriadis N.C., et al. Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model. Neurobiol Dis 2011, 44:327-339.
16. Kushnir M., Dresner E., Mandel S., Gozes I. Silencing of the ADNP-family member, ADNP2, results in changes in cellular viability under oxidative stress. J Neurochem 2008, 105:537-545.
17. Mandel S., Gozes I. Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex. J Biol Chem 2007, 282:34448-34456.
18. Mandel S., Rechavi G., Gozes I. Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Dev Biol 2007, 303:814-824.
19. Mandel S., Spivak-Pohis I., Gozes I. ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance. J Mol Neurosci 2008, 35:127-141.
20. Matsuoka Y., Jouroukhin Y., Gray A.J., Ma L., Hirata-Fukae C., Li H.F., et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2008, 325:146-153.
21. Merenlender-Wagner A., Pikman R., Giladi E., Andrieux A., Gozes I. NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse-a microtubule-deficient model of schizophrenia. Peptides 2010, 31:1368-1373.
22. Morimoto B.H., de Lannoy I., Fox A.W., Gozes I., Stewart A.J. Davunetide: pharmacokinetics and distribution to brain after intravenous or intranasal administration to rat. Chim Oggi/Chemistry Today 2009, 27:16-20.
23. Mosch K., Franz H., Soeroes S., Singh P.B., Fischle W. HP1 recruits activity-dependent neuroprotective protein to H3K9me3 marked pericentromeric heterochromatin for silencing of major satellite repeats. PLoS One 2011, 6:e15894.
24. Pascual M., Guerri C. The peptide NAP promotes neuronal growth and differentiation through extracellular signal-regulated protein kinase and Akt pathways, and protects neurons co-cultured with astrocytes damaged by ethanol. J Neurochem 2007, 103:557-568.
25. Pinhasov A., Mandel S., Torchinsky A., Giladi E., Pittel Z., Goldsweig A.M., et al. Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res 2003, 144:83-90.
26. Poggi S.H., Goodwin K., Hill J.M., Brenneman D.E., Tendi E., Schinelli S., et al. The role of activity-dependent neuroprotective protein in a mouse model of fetal alcohol syndrome. Am J Obstet Gynecol 2003, 189:790-793.
27. Sharma N.K., Sethy N.K., Meena R.N., Ilavazhagan G., Das M., Bhargava K. Activity-dependent neuroprotective protein (ADNP)-derived peptide (NAP) ameliorates hypobaric hypoxia induced oxidative stress in rat brain. Peptides 2011, 32:1217-1224.
28. Shiryaev N., Jouroukhin Y., Giladi E., Polyzoidou E., Grigoriadis N.C., Rosenmann H., et al. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 2009, 34:381-388.
29. Shiryaev N., Pickman R., Giladi E., Gozes I. Protection against tauopathy by the drug candidates NAP (Davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Curr Pharm Design 2011, 17:2112-2603. Review.
30. Sokolowska P., Passemard S., Mok A., Schwendimann L., Gozes I., Gressens P. Neuroprotective effects of NAP against excitotoxic brain damage in the newborn mice: implications for cerebral palsy. Neuroscience 2011, 173:156-168.
31. Sudo H., Baas P.W. Strategies for diminishing katanin-based loss of microtubules in tauopathic neurodegenerative diseases. Hum Mol Genet 2011, 20:763-778.
32. Vulih-Shultzman I., Pinhasov A., Mandel S., Grigoriadis N., Touloumi O., Pittel Z., et al. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther 2007, 323:438-449.
33. Zamostiano R., Pinhasov A., Gelber E., Steingart R.A., Seroussi E., Giladi E., et al. Cloning and characterization of the human activity-dependent neuroprotective protein. J Biol Chem 2001, 276:708-714.
34. Zemlyak I., Manley N., Vulih-Shultzman I., Cutler A.B., Graber K., Sapolsky R.M., et al. The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy. J Neurochem 2009, 111:1252-1263.
35. Zemlyak I., Sapolsky R., Gozes I. NAP protects against cytochrome c release: inhibition of the initiation of apoptosis. Eur J Pharmacol 2009, 618:9-14.